Loading
AT
Arch Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ABRAMS MICHAEL S, was filed 08 Sept 2023.
Arch Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Arch Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Arch Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 8 September 2023.
Looking back to 2016, when coverage begins, insiders filed 4 purchases and no sales.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
22
Thresholds
n/a
Buy Volume
€6,960
4 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended September 2023 · cache
Income statement
Net income-US$6M
Last declaration on 8 September 2023
Declarations22 total
10,292 shares@ US$0.275100.0% of flowCommon StockSEC:0001437749-23-025515:0
Canonical exit: 29 Nov 2023 (T+90)
10,292 shares@ US$0.275100.0% of flowCommon StockSEC:0001437749-23-025513:0
Canonical exit: 29 Nov 2023 (T+90)
6,862 shares@ US$0.275100.0% of flowCommon StockSEC:0001437749-23-025514:0
Canonical exit: 29 Nov 2023 (T+90)
72,435 sharesCommon StockSEC:0001415889-22-007596:0
108,652 sharesCommon StockSEC:0001415889-22-007594:0
108,652 sharesCommon StockSEC:0001415889-22-007598:0
150,000 shares0Common StockSEC:0001104659-21-103581:0
454,546 sharesCommon StockSEC:0001104659-20-075860:0
275,000 shares0Common StockSEC:0001144204-18-039094:0
110,000 shares0Common StockSEC:0001144204-18-039096:0
220,000 shares0Common StockSEC:0001144204-18-039091:0
360,000 shares0Common StockSEC:0001144204-18-039095:0
30,000 shares@ US$0.37100.0% of flowCommon StockSEC:0001144204-18-038834:0
200,000 shares0Common StockSEC:0001144204-17-006095:0
500,000 shares0Common StockSEC:0001144204-17-006091:0
400,000 shares0Common StockSEC:0001144204-17-006092:0
650,000 shares0Common StockSEC:0001144204-17-006093:0
111,111 sharesCommon StockSEC:0001144204-16-105769:0
Canonical exit: 24 Aug 2016 (T+90)
103,000 shares0Common StockSEC:0001144204-16-099139:0
30,000 shares0Common StockSEC:0001144204-16-099137:0
1,130,000 shares0Common StockSEC:0001144204-16-099141:0
737,000 shares0Common StockSEC:0001144204-16-099135:0
22 of 22 declarations
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a United States-based biotechnology and medical-device company that should be viewed as a specialized small-cap healthcare story rather than a broad pharmaceutical platform. The company was incorporated in 2009 in Nevada, originally under the name Almah, Inc., and later rebranded as Arch Therapeutics, Inc. Public filings describe Arch as a development-stage biotechnology company, and company materials place its headquarters in Framingham, Massachusetts, which situates it within a major U.S. life-sciences cluster. The stock is associated with the U.S. public markets and is referenced in the context of OTC/US equities tied to the NASDAQ/NYSE ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537561/000110465919065500/tm1919813d1_10k.htm?utm_source=openai))
Arch’s core strategy is built around its proprietary AC5® self-assembling technology platform. The company says the platform is designed to rapidly create a physical barrier when applied to tissue, helping achieve hemostasis, control fluid leakage, and manage wounds during surgery, trauma, and interventional care. Its flagship development and commercial efforts center on AC5-branded products, including AC5 Topical Hemostat, AC5 Surgical Hemostat, and the AC5 Advanced Wound System. In practical terms, Arch is targeting surgeon and wound-care workflows where fast bleeding control and tissue protection matter, and it positions its products as a differentiated alternative to traditional hemostatic agents and wound-care materials. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537561/000110465919065500/tm1919813d1_10k.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Arch operates in a crowded and highly regulated field dominated by much larger medtech and wound-care companies. That means its commercial opportunity depends not only on product performance, but also on clinical acceptance, reimbursement dynamics, distribution relationships, and the ability to scale sales efficiently. The company’s small size and development-to-commercialization profile make it more speculative than established healthcare peers, but they also provide optionality if its AC5 platform gains traction in targeted procedural and wound-care segments. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537561/000110465919065500/tm1919813d1_10k.htm?utm_source=openai))
Geographically, Arch remains primarily U.S.-focused, although it has disclosed a CE mark for AC5 Topical Hemostat in Europe, indicating that the platform has had at least some regulatory reach outside the United States. Recent company communications have emphasized presentations at wound-care conferences and continued commercialization efforts, including adding contract sales representatives to support the AC5 Advanced Wound System. For investors in France, Belgium, and Switzerland, Arch should be analyzed as a micro-cap medtech company with a potentially interesting barrier-and-hemostasis technology, but with meaningful execution, financing, and adoption risk. The central question is whether the company can convert its technology narrative into sustainable revenue growth. ([ir.archtherapeutics.com](https://ir.archtherapeutics.com/press-releases?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
